However, most MC4R agonist drug candidates developed as potential therapeutics for treating obesity failed in the clinic despite preclinical efficacy, due to lack of efficacy and side effects. The gene discussed is MC4R; the disease is obesity due to melanocortin 4 receptor deficiency.